Antibe Therapeutics (TSE:ATE) Shares Up 13.5% – Still a Buy?

Antibe Therapeutics Inc. (TSE:ATE)’s share price shot up 13.5% during trading on Monday . The stock traded as high as C$0.35 and last traded at C$0.30. 167,042 shares traded hands during mid-day trading, an increase of 23% from the average session volume of 135,475 shares. The stock had previously closed at C$0.26.

Antibe Therapeutics Stock Up 13.5 %

The stock has a market cap of C$15.64 million, a P/E ratio of -0.84 and a beta of 0.19. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.06 and a quick ratio of 9.58. The business has a 50 day moving average price of C$0.30.

About Antibe Therapeutics

Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs).